(Q48738441)

English

Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

adaptive radiation therapy

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Srinivas Kondalsamy-Chennakesavan

4

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

12

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

object named as

David Wyld

7

0 references

object named as

Peter Sykes

11

0 references

Andreas Obermair

object named as

Andreas Obermair

1

0 references

object named as

Lewis C Perrin

10

0 references

object named as

James L Nicklin

9

0 references

author name string

Linda Mileshkin

2

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

Katharina Bolz

3

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

Robyn Cheuk

5

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

Paul Vasey

6

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

Jeffrey Goh

8

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

language of work or name

0 references

publication date

3 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

120

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

2

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

179-184

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

Outcomes in surgical stage I uterine papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

The Queensland Cancer Risk Study: general population norms for the Functional Assessment of Cancer Therapy-General (FACT-G).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Smallest real difference, a link between reproducibility and responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Estimating clinically significant differences in quality of life outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Quality of life and psychosocial adjustment in gynecologic cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

The effect of prolonged cycles of chemotherapy on quality of life in gynaecologic cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.039

7 January 2021

Identifiers

10.1016/J.YGYNO.2010.10.039

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21126755

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48738441&oldid=2208962385"